Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction

Thrombosis Research

Volumn 118, Issue 2, 2006, Pages 221-227

  Tziakas, Dimitrios N ^a   Chalikias, Georgios K ^a   Hatzinikolaou, Eleni I ^a   Stakos, Dimitrios A ^a   Tentes, Ioannis K ^a   Kortsaris, Alexandros ^a   Hatseras, Dimitrios I ^a   Kaski, Juan Carlos ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Matrix metalloproteinases; Plaque instability; Plasmin plasminogen; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; GLYCERYL TRINITRATE; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYTIC THERAPY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

AGED; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYOCARDIAL INFARCTION; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33744532744     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.07.014     Document Type: Article

References (35)

1. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 (1995) 657-671
2. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91 (1995) 2844-2850
3. Farb A., Burke A.P., Tang A.L., Liang L.Y., Mannan P., Smialek J., et al. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden cardiac death. Circulation 93 (1996) 1354-1363
4. Rioufol G., Finet G., Ginon I., Andre-Fouet X., Rossi R., Vialle E., et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome. A three vessel intravascular ultrasound study. Circulation 106 (2002) 804-808
5. Goldstein J.A., Demetriou D., Grines C.L., Pica M., Shoukfeh M., and O'Neill W.W. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 343 (2000) 915-922
6. Asakura M., Ueda Y., Yamaguchi O., Adachi T., Hirayama A., Hori M., et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol 37 (2001) 1284-1288
7. Casscells W., Hathorn B., David M., Krabach T., Vaughan W.K., McAllister H.A., et al. Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis. Lancet 347 (1996) 1447-1451
8. Avanzas P., Arroyo-Espliguero R., Cosin-Sales J., Aldama G., Pizzi C., Quiles J., et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 90 (2004) 847-852
9. Guazzi M., Bussotti M., Grancini L., De Cesare N., Guazzi M., Pera I., et al. Evidence of multifocal activity of coronary disease in patients with acute myocardial infarction. Circulation 96 (1997) 1145-1151
10. Topol E.J. Acute myocardial infarction: thrombolysis. Heart 83 (2000) 122-126
11. Willerson J.T., and Zoldhelyi P. Future directions in thrombolysis. Clin Cardiol 22 (1999) IV44-IV53
12. Becker P.C. Reocclusion following successful thrombolysis: emerging concepts. Cardiology 82 (1993) 265-273
13. Shah P.K. Reduced tissue factor pathway inhibitor-1 after pharmacological thrombolysis. An epiphenomenon or potential culprit in rethrombosis?. Circulation 105 (2002) 270-271
14. Falk E. Pathogenesis of atherosclerosis. Am Heart J 138 (1999) S421-S425
15. Jones C.B., Sane D.C., and Herrington D.M. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 59 (2003) 812-823
16. Woessner J.F.J., and Nagase H. Activation of zymogen forms of MMPs. Matrix metalloproteinases and TIMPs (2000), Oxford University Press, New York, NY 72-86
17. Lee E., Vaughan D.E., Parikh S.H., Grodzinsky A.J., Libby P., Lark M.W., et al. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ Res 78 (1996) 44-49
18. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 21 (2000) 1502-1513
19. ACC Clinical Data Standards. American college of cardiology key data elements and definition for measuring the clinical management and outcomes of patients with acute coronary syndromes. JACC 38 (2001) 2114-2130
20. Antman E., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M., et al. ACC/AHA guidelines for the management of patient with ST-elevation myocardial infarction. Circulation 110 (2004) e82-e292
21. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682
22. Horstmann S., Kalb P., Koziol J., Gardner H., and Wagner S. Profiles of matrix metalloproteinases, their inhibitors and laminin in stroke patients. Influence of different therapies. Stroke 34 (2003) 2165-2172
23. Wang X., Lee S.R., Arai K., Lee S.R., Tsuji K., Rebeck G.W., et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9 (2003) 1313-1317
24. Linjen H.R. Non-haemostatic role for blood coagulation proteases and their receptors. Biochem Soc Trans 30 (2002) 163-167
25. Collen D. Role of the plasminogen system in fibrin-homeostasis and tissue remodelling. The Ham-Wasserman lecture. Hematology (2001) 1-9
26. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 378 (1997) 151-160
27. Galis Z., Sukhova G.K., Kranzhofer R., Clark S., and Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 92 (1995) 402-406
28. Henney A.M., Wakely P.R., Davies M.J., Foster K., Hembry R., Murphy G., et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A 88 (1991) 8154-8158
29. Galis S.Z., Muszynski M., Sukhova G.K., Simon-Morrisey E., and Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 748 (1995) 501-507
30. Newman K.M., Jean Claude J., Li H., Scholes J.V., Ogata Y., Nagase H., et al. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg 20 (1994) 814-820
31. Lupu F., Heim D.A., Bachmann F., Humi M., Kakkar V.V., and Kruithof E.K. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 15 (1995) 1444-1455
32. Steins M.B., Padro T., Li C.X., Mesters R.M., Ostermann H., Hammel D., et al. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 145 (1999) 173-180
33. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., et al. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. JACC 32 (1998) 368-372
34. Gyongyosi M., Glogar D., Weidinger F., Domanovits H., Laggner A., Wojta J., et al. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non ST -segment elevation myocardial infarction. Am Heart J 147 (2004) 158-164
35. Okamoto T., Akaike T., Sawa T., Miyamoto Y., van der Vliet A., and Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 276 (2001) 29569-29602